Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
Yi-Long Lung Cancer Wu, Ying Cheng, Xiangdong Zhou et al. · The Lancet Oncology · 2017
Cited by 1,207 works. doi:10.1016/s1470-2045(17)30608-3
Authors
- Yi-Long Lung Cancer Wu
- Ying Cheng
- Xiangdong Zhou
- Ki Hyeong Lee
- Kazuhiko Nakagawa
- Seiji Niho
- Fumito Tsuji
- R. Linke
- Rafael Rosell
- Jesus Corral
- Maria Rita Migliorino
- Adam Płużański
- Eric I. Sbar
- Jane Liang White
- Sashi Nadanaciva
- Rickard Sandin
- Tony S.K. Mok
References
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
- EuroQol - a new facility for the measurement of health-related quality of life
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- Interpreting the significance of changes in health-related quality-of-life scores.
- Partial Residuals for The Proportional Hazards Regression Model
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study